Hepatology Research最新文献

{"title":"Differential Eligibility for Immune Checkpoint Inhibitor-Based Therapy at Recurrence: A Potential Explanation for Improved Survival in Viral Hepatocellular Carcinoma","authors":"Kazuya Kariyama, Kazuhiro Nouso","doi":"10.1111/hepr.70182","DOIUrl":"10.1111/hepr.70182","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1301-1302"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Male Patients With β-Catenin-Positive Atypical Hepatocellular Neoplasm Arising in Inflammatory Hepatocellular Adenoma: A Case Report","authors":"Shingo Yamasaki,&nbsp;Akihiko Takagi,&nbsp;Daisuke Yamamoto,&nbsp;Ryuta Muraki,&nbsp;Satoshi Tokuda,&nbsp;Takeo Toda,&nbsp;Makoto Obayashi,&nbsp;Kazumori Arai,&nbsp;Hideyuki Kanemoto","doi":"10.1111/hepr.70185","DOIUrl":"10.1111/hepr.70185","url":null,"abstract":"<div>\u0000 \u0000 <p>Hepatocellular adenoma (HCA) is a benign tumor that predominantly occurs in young female, whereas male sex is considered a risk factor for malignant transformation. Recent studies from Asian countries have reported a different sex distribution pattern. However, there are few reports of HCA in Japan. We report a case of a male patient, diagnosed with inflammatory HCA (IHCA) including small areas of atypical hepatocellular neoplasm. A 66-year-old man was found to have a 6 cm tumor protruding extrahepatically from segment 6 (S6) of the liver on imaging. Differential diagnoses included focal nodular hyperplasia (FNH), HCA, hemangioma, and did not exclude hepatocellular carcinoma (HCC). Due to the risk of rupture, laparoscopic partial hepatectomy of S6 was performed. Although there was a lack of consensus among experts regarding the diagnosis, histological and immunohistochemical analyses led to a diagnosis of IHCA with small areas of <i>β</i>-catenin-positive atypical hepatocellular neoplasm.</p>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1292-1298"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated Burden and Long-Term Projections of Chronic Hepatitis B and C in Japan: A Nationwide Markov Modeling Study","authors":"Junko Tanaka,&nbsp;Akemi Kurisu,&nbsp;Ko Ko,&nbsp;Aya Sugiyama,&nbsp;Tomoyuki Akita","doi":"10.1111/hepr.70174","DOIUrl":"10.1111/hepr.70174","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain major causes of liver-related morbidity and mortality worldwide. Although Japan has implemented nationwide screening and treatment programs for decades, updated nationwide estimates and long-term projections are limited. We aimed to estimate the number of carriers and patients in Japan in 2020 and to project through 2050.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The carriers were classified into six categories: undiagnosed carriers, patients in care, diagnosed but not linked to care, new infections, cured, and deceased. Multiple nationwide data sources—including the National Database of Health Insurance Claims (NDB), public statistics, clinical information, and large-scale blood donor screening data—were integrated to estimate the size of each category. The Markov model incorporating treatment status and liver disease progression was used to simulate annual changes from 2021 to 2050.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2020, the total estimated number of carriers and patients was 1,104,406–1,424,420 (532,159–618,684, aged ≤ 69 years), including HBV: 923,893–940,647 (454,167–461,408, ≤ 69 years) and HCV: 180,513–483,773 (77,992–157,276, ≤ 69 years). Diagnosis and treatment rates exceeded WHO 2030 targets for HBV (95% and 83%–84%; 94% and 99%–100%, ≤ 69 years) and approached targets for HCV (82%–93% and 78%–100%; 75%–88% and 98%–100%, ≤ 69 years). Under current conditions, HCV infections are projected to decline to &lt; 20,000 by 2050, whereas HBV will decrease more gradually to 200,000.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The chronic HBV and HCV burden in Japan declined markedly, particularly for HCV, reflecting progress in prevention, diagnosis, and treatment and offering a model for hepatitis elimination.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1213-1224"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20-Year Population-Based Study","authors":"Jur-Shan Cheng,&nbsp;Wei-Ting Chen,&nbsp;Tsung-Hsing Chen,&nbsp;Wei-Pin Lin,&nbsp;Cheng-Jen Chen,&nbsp;Chung-Wei Su,&nbsp;Cheng-Yu Lin,&nbsp;Chi-Huan Wu,&nbsp;Kai-Feng Sung,&nbsp;Puo-Hsien Le,&nbsp;Ming-Ling Chang","doi":"10.1111/hepr.70177","DOIUrl":"10.1111/hepr.70177","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Aims</h3>\u0000 \u0000 <p>The economic burden of primary biliary cholangitis (PBC) among Asians has not been investigated at the population level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PBC patients were identified via the Taiwan National Health Insurance administrative database. Health services, including inpatient and outpatient activities, were used to estimate medical costs between 2002 and 2021. Inflation was adjusted according to the consumer price index.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 4772 PBC patients were enrolled. The overall total (inpatient and outpatient) [average annual percent change (AAPC): 14.69%, <i>p</i> &lt; 0.0001], overall inpatient (AAPC: 14.12%, <i>p</i> &lt; 0.0001), overall outpatient (AAPC: 16.64%, <i>p</i> &lt; 0.0001), and mean outpatient medical costs (AAPC: 2.94%, <i>p</i> &lt; 0.0001) increased over time. Compared with males, females had lower mean (<i>p</i> &lt; 0.0001) total costs. The mean inpatient cost was higher among southern than among northern Taiwan PBC patients (<i>p</i> = 0.0024). Extrahepatic costs were lower than hepatic costs (<i>p</i> &lt; 0.0001), with nonhepatocellular carcinoma (non-HCC) and diabetes being the main causes. The annual cost of cirrhosis, HCC and liver transplantation was 20,417 new Taiwan dollars (NTD). Age ≥ 80 years (estimated ß: 0.245, <i>p</i> = 0.028), female sex (−0.203, <i>p</i> &lt; 0.0001), and dyslipidemia (−0.138, <i>p</i> &lt; 0.0001) were associated independently with individual total costs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The overall (total, inpatient and outpatient) and mean outpatient costs for PBC patients increased over time. Special attention and tailored treatments should be given to PBC subgroups, including males, elderly people, southern Taiwan residents, those with hepatic events, and those with diabetes, as this approach might effectively reduce medical costs. A new drug that is effective and costs ≤ NTD 20,417/year would benefit PBC patients in Taiwan.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1235-1245"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Using Serum Creatinine-to-Cystatin C Ratio to Predict Sarcopenia in Patients With Liver Cirrhosis”","authors":"Weiming Wang,&nbsp;Miaofeng Wang,&nbsp;Lifeng Tang","doi":"10.1111/hepr.70183","DOIUrl":"10.1111/hepr.70183","url":null,"abstract":"","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1303-1304"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease","authors":"Yoshihito Uchida,&nbsp;Naoto Soma,&nbsp;Shohei Tsuji,&nbsp;Satsuki Ando,&nbsp;Kayoko Sugawara,&nbsp;Masamitsu Nakao,&nbsp;Nobuaki Nakayama,&nbsp;Yukinori Imai,&nbsp;Suguru Mizuno,&nbsp;Satoshi Mochida","doi":"10.1111/hepr.70189","DOIUrl":"10.1111/hepr.70189","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Zinc deficiency is common in patients with chronic liver disease and is associated with hepatic encephalopathy, malnutrition, and poor prognosis. Zinc histidine hydrate was recently approved in Japan for the treatment of hypozincemia; however, clinical evidence regarding switching from zinc acetate hydrate remains limited. This study evaluated the short-term efficacy and safety of switching to zinc histidine hydrate in patients with chronic liver disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center prospective single-arm switching study enrolled patients receiving zinc acetate hydrate. Patients were switched to zinc histidine hydrate at an equivalent elemental zinc dose. Serum zinc, ammonia, and copper levels were evaluated at 4 and 12 weeks. Appetite was assessed at baseline and 4 weeks using the Council on Nutrition Appetite Questionnaire Japanese version (CNAQ-J) and the Functional Assessment of Anorexia/Cachexia Therapy–Anorexia/Cachexia Subscale (FAACT A/CS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-two patients were switched to zinc histidine hydrate, and 40 were included in the analysis. The median serum zinc level increased significantly from 83 μg/dL at baseline to 101 μg/dL at 4 weeks (<i>p</i> = 0.0003) and remained significantly elevated at 96 μg/dL at 12 weeks (<i>p</i> = 0.0005). Serum ammonia and copper levels showed no significant changes. Appetite-related scores improved significantly after switching, with increases in CNAQ-J and FAACT A/CS scores at 4 weeks. No overt hepatic encephalopathy or clinically significant adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Switching from zinc acetate hydrate to zinc histidine hydrate rapidly increased serum zinc levels and improved appetite. Zinc histidine hydrate may represent a practical option for optimizing zinc supplementation in patients with chronic liver disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1286-1291"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics, Predictive Factors, and the Impact of Antithrombotic Therapy on Bleeding Events in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab","authors":"Fujimasa Tada,&nbsp;Atsushi Hiraoka,&nbsp;Hideko Ohama,&nbsp;Toshifumi Tada,&nbsp;Masashi Hirooka,&nbsp;Kazuya Kariyama,&nbsp;Joji Tani,&nbsp;Masanori Atsukawa,&nbsp;Koichi Takaguchi,&nbsp;Ei Itobayashi,&nbsp;Shinya Fukunishi,&nbsp;Kunihiko Tsuji,&nbsp;Toru Ishikawa,&nbsp;Kazuto Tajiri,&nbsp;Hironori Tanaka,&nbsp;Hidenori Toyoda,&nbsp;Chikara Ogawa,&nbsp;Takashi Nishimura,&nbsp;Takeshi Hatanaka,&nbsp;Satoru Kakizaki,&nbsp;Kazuhito Kawata,&nbsp;Atsushi Naganuma,&nbsp;Hisashi Kosaka,&nbsp;Tomomitsu Matono,&nbsp;Yoshihide Ueda,&nbsp;Hidekatsu Kuroda,&nbsp;Yutaka Yata,&nbsp;Hiroki Nishikawa,&nbsp;Michitaka Imai,&nbsp;Tomoko Aoki,&nbsp;Hironori Ochi,&nbsp;Jumpei Okamura,&nbsp;Hideyuki Tamai,&nbsp;Shinichiro Nakamura,&nbsp;Yoshiko Nakamura,&nbsp;Osamu Yoshida,&nbsp;Kazuhiro Nouso,&nbsp;Asahiro Morishita,&nbsp;Norio Itokawa,&nbsp;Tomomi Okubo,&nbsp;Taeang Arai,&nbsp;Akemi Tsutsui,&nbsp;Takuya Nagano,&nbsp;Kazunari Tanaka,&nbsp;Yuichi Koshiyama,&nbsp;Yuki Kanayama,&nbsp;Hidenao Noritake,&nbsp;Shohei Komatsu,&nbsp;Takumi Fukumoto,&nbsp;Takanori Matsuura,&nbsp;Soo Ki Kim,&nbsp;Hirayuki Enomoto,&nbsp;Kosuke Matsui,&nbsp;Masaki Kaibori,&nbsp;Yoichi Hiasa,&nbsp;Masatoshi Kudo,&nbsp;Takashi Kumada,&nbsp;the Real-life Practice Experts for HCC (RELPEC) Study Group and hepatocellular carcinoma experts from 48 clinics in Japan (HCC 48) Group","doi":"10.1111/hepr.70190","DOIUrl":"10.1111/hepr.70190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Atezolizumab plus bevacizumab (Atez/Bev) in unresectable hepatocellular carcinoma (uHCC) is a standard first-line therapy, but bleeding-related adverse events (BL-AEs) remain clinically concerning, particularly in real-world patients with advanced tumors, portal hypertension, or undergoing antithrombotic therapy (ATT). We aimed to evaluate whether ATT increases bleeding risk, identify pretreatment factors associated with BL-AEs, and assess the impact of bleeding on progression-free survival (PFS) and overall survival (OS) in patients with uHCC treated with Atez/Bev.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter retrospective study included 981 patients with uHCC treated with Atez/Bev. BL-AEs were identified by clinical assessment, imaging, or endoscopy. Predictors of BL-AEs were analyzed using logistic regression. Survival outcomes were compared by Kaplan–Meier method, with inverse probability weighting (IPW) applied to adjust for baseline imbalances.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>BL-AEs occurred in 102 patients (10.4%) and led to treatment discontinuation in 2.7% patients. Independent predictors of BL-AEs included advanced tumor burden components, such as Vp ≥ 3 portal vein invasion and extrahepatic metastasis. Neither ATT nor portal hypertension–related factors were associated with bleeding risk. PFS did not differ between groups, whereas OS was significantly shorter in the BL group before IPW adjustment than after IPW adjustment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>During Atez/Bev therapy, BL-AEs were primarily associated with advanced tumor burden rather than with ATT or baseline portal hypertension–related factors. Although BL-AEs were associated with poorer OS, this should be interpreted cautiously, as bleeding may reflect aggressive tumor biology rather than a direct mortality cause. Careful monitoring for bleeding complications may be required in patients with advanced tumor burden receiving Atez/Bev.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1274-1285"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preventive Effect of Mineralocorticoid Receptor Antagonists Against Proteinuria Induced by Atezolizumab Plus Bevacizumab Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study","authors":"Tomoki Hori,&nbsp;Kazuhiro Yamamoto,&nbsp;Hiroshi Aoi,&nbsp;Yusuke Koizumi,&nbsp;Makoto Kuromatsu,&nbsp;Aiko Fukui,&nbsp;Hiroyo Okamoto,&nbsp;Atsushi Hirata,&nbsp;Kentaro Shinmori,&nbsp;Yuki Imanaka,&nbsp;Miyu Namba,&nbsp;Keisuke Nakanishi,&nbsp;Syunsuke Kitamura,&nbsp;Hideo Tsushima,&nbsp;Ikuko Yano,&nbsp;Kei Moriya,&nbsp;Masaru Matsui,&nbsp;Shigeki Ikushima","doi":"10.1111/hepr.70176","DOIUrl":"10.1111/hepr.70176","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Mineralocorticoid receptor antagonists (MRAs) reduce proteinuria in chronic kidney disease, but their role in preventing bevacizumab-induced proteinuria remains uncertain. This study aimed to assess whether MRAs prevent proteinuria caused by atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present retrospective study included patients with advanced hepatocellular carcinoma who received atezolizumab plus bevacizumab between September 2020 and December 2023 at five institutions in Japan. The primary outcome was the time to onset of grade ≥ 2 proteinuria during the first 6 months of bevacizumab treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 177 patients, 26 received MRAs and 151 did not. The onset of grade ≥ 2 proteinuria occurred significantly later in the MRA group than in the non-MRA group (<i>p</i> = 0.018). In multivariate Cox hazard analysis, diabetes (hazard ratio [HR] = 1.81, 95% confidence interval [CI]: 1.00–3.25, <i>p</i> = 0.049), higher average systolic blood pressure (HR = 2.08, 95% CI: 1.16–3.73, and <i>p</i> = 0.014), and MRA use (HR = 0.21, 95% CI: 0.047–0.90, and <i>p</i> = 0.035) were independently associated with time to grade ≥ 2 proteinuria. Bevacizumab interruption due to proteinuria within 6 months was lower in the MRA group than in the non-MRA group (0% vs. 13.2% and <i>p</i> = 0.049).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>MRA can suppress moderate or greater proteinuria induced by atezolizumab plus bevacizumab therapy and reduce the rate of bevacizumab interruption.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1225-1234"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70176","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Sofosbuvir/Velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: A Retrospective Multicenter Cohort Study","authors":"Satoru Kakizaki,&nbsp;Tadashi Ikegami,&nbsp;Takeshi Hatanaka,&nbsp;Yuhei Suzuki,&nbsp;Takashi Hoshino,&nbsp;Atsushi Naganuma,&nbsp;Daichi Takizawa,&nbsp;Hirotaka Arai,&nbsp;Takashi Ueno,&nbsp;Keisuke Iizuka,&nbsp;Takahiro Arisaka,&nbsp;Yuichi Majima,&nbsp;Makoto Iijima,&nbsp;Shigeo Tano,&nbsp;Toshiyuki Tahara,&nbsp;Masahiro Araki,&nbsp;Toshiro Kamoshida,&nbsp;Yoshinari Takaoka,&nbsp;Hidekazu Kurata,&nbsp;Yukimura Fukaya,&nbsp;Kuniaki Fukuda,&nbsp;Atsuko Soeda,&nbsp;Takayoshi Suga,&nbsp;Shuichi Saito,&nbsp;Toru Fukuchi,&nbsp;Satoshi Takakusagi,&nbsp;Hitoshi Takagi,&nbsp;Katsuhiko Horiuchi,&nbsp;Yuki Kanayama,&nbsp;Toshiya Ohtake,&nbsp;Hiroki Tojima,&nbsp;Yuichi Yamazaki,&nbsp;Shunji Watanabe,&nbsp;Kouichi Miura,&nbsp;Naoki Morimoto,&nbsp;Liver Investigators in the Northern Kanto Study (LINKS) group","doi":"10.1111/hepr.70172","DOIUrl":"10.1111/hepr.70172","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sofosbuvir/velpatasvir (SOF/VEL) treatment for hepatitis C virus (HCV)–related decompensated cirrhosis has been shown to achieve a high sustained virologic response (SVR) rate and to improve liver function. However, limited data are available regarding the association between improvements in liver function and long-term survival. This multicenter study aimed to evaluate longitudinal changes in liver function and factors associated with long-term prognosis in patients treated with SOF/VEL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ninety-one patients who received SOF/VEL for HCV-related decompensated cirrhosis between March 2019 and December 2021 were enrolled. SVR rates, changes in Child–Pugh scores at 12, 24, 48, 72, and 120 weeks after treatment, changes in albumin–bilirubin (ALBI) scores, and overall survival (OS) were assessed. The impact of post-treatment ALBI improvement on prognosis was examined, and its predictive ability for 60-month OS was evaluated using receiver operating characteristic analysis. Survival was compared using the Kaplan–Meier method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age was 68.0 years; 36.3% of patients were male, and 24.2% had a history of hepatocellular carcinoma. SVR was achieved in 96.7% of patients. The median observation period was 57.0 months (IQR, 43.0–72.0), and 27 patients (29.7%) died during the observation period. Child–Pugh scores improved from the end of treatment and continued to improve; at 120 weeks, 55.9% of patients had scores of 5 or 6. The median OS was not reached, and the 5-year survival rate was 73.2%. ALBI improvement predicted 60-month OS with a sensitivity of 0.494, a specificity of 0.851, and an optimal cutoff value of a decrease in ALBI score of ≥ 0.103. Patients with ALBI improvement showed significantly better OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SOF/VEL therapy achieved high SVR rates and demonstrated that post-treatment improvement in the ALBI score is strongly associated with a favorable long-term prognosis in patients with decompensated cirrhosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1191-1201"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab","authors":"Kazunari Tanaka,&nbsp;Kunihiko Tsuji,&nbsp;Atsushi Hiraoka,&nbsp;Toshifumi Tada,&nbsp;Masashi Hirooka,&nbsp;Kazuya Kariyama,&nbsp;Joji Tani,&nbsp;Masanori Atsukawa,&nbsp;Koichi Takaguchi,&nbsp;Ei Itobayashi,&nbsp;Shinya Fukunishi,&nbsp;Toru Ishikawa,&nbsp;Kazuto Tajiri,&nbsp;Hironori Tanaka,&nbsp;Hidenori Toyoda,&nbsp;Chikara Ogawa,&nbsp;Takashi Nishimura,&nbsp;Takeshi Hatanaka,&nbsp;Satoru Kakizaki,&nbsp;Kazuhito Kawata,&nbsp;Atsushi Naganuma,&nbsp;Hisashi Kosaka,&nbsp;Tomomitsu Matono,&nbsp;Yoshihide Ueda,&nbsp;Hidekatsu Kuroda,&nbsp;Yutaka Yata,&nbsp;Hiroki Nishikawa,&nbsp;Michitaka Imai,&nbsp;Tomoko Aoki,&nbsp;Hironori Ochi,&nbsp;Jumpei Okamura,&nbsp;Hideyuki Tamai,&nbsp;Shinichiro Nakamura,&nbsp;Yoshiko Nakamura,&nbsp;Osamu Yoshida,&nbsp;Kazuhiro Nouso,&nbsp;Asahiro Morishita,&nbsp;Norio Itokawa,&nbsp;Tomomi Okubo,&nbsp;Taeang Arai,&nbsp;Akemi Tsutsui,&nbsp;Takuya Nagano,&nbsp;Fujimasa Tada,&nbsp;Hideko Ohama,&nbsp;Yuichi Koshiyama,&nbsp;Yuki Kanayama,&nbsp;Hidenao Noritake,&nbsp;Shohei Komatsu,&nbsp;Takumi Fukumoto,&nbsp;Takanori Matsuura,&nbsp;Soo Ki Kim,&nbsp;Hirayuki Enomoto,&nbsp;Kosuke Matsui,&nbsp;Masaki Kaibori,&nbsp;Yoichi Hiasa,&nbsp;Masatoshi Kudo,&nbsp;Takashi Kumada,&nbsp;the Real-Life Practice Experts for HCC (RELPEC) Study Group and Hepatocellular Carcinoma Experts From 48 Clinics in Japan (HCC 48) Group","doi":"10.1111/hepr.70178","DOIUrl":"10.1111/hepr.70178","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Systemic therapy is the standard care for patients with hepatocellular carcinoma (HCC) and extrahepatic metastases. However, the relative prognostic importance of the intrahepatic tumor burden versus the extent of extrahepatic disease in the era of immune checkpoint inhibitor-based therapy remains unclear. This study aimed to clarify the prognostic impact of intrahepatic tumor burden in patients with metastatic HCC treated with atezolizumab plus bevacizumab (Atez/Bev).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter retrospective study of patients with HCC and extrahepatic metastases who received first-line Atez/Bev therapy. The intrahepatic tumor burden was assessed using established radiologic parameters, including tumor size, number, and vascular invasion, and the patients were stratified according to the intrahepatic disease severity. Overall survival (OS) was defined as the primary endpoint. Survival analyses were carried out using the Kaplan–Meier method and Cox proportional hazards models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 306 patients were included in the study. During a median follow-up of 13.5 months, the OS differed markedly according to the intrahepatic tumor burden and macrovascular invasion. The median OS was 17.8 months in the mild MVI group, 12.2 months in the severe MVI group, 29.8 months in the UT7 in group, and 15.2 months in the UT7 out group (<i>p</i> &lt; 0.001). In multivariate analysis, the intrahepatic tumor burden remained an independent predictor of OS, whereas the extent and number of extrahepatic metastatic sites were not significantly associated with prognosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In metastatic HCC treated with atezolizumab plus bevacizumab, intrahepatic tumor burden was associated with overall survival and may be useful for risk stratification and treatment optimization.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 8","pages":"1246-1253"},"PeriodicalIF":3.7,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}